CEO Ian Mortimer Buys $1.12M of Xenon Stock Near 52-Week Low
XENE is trading near its 52-week low of $36.07 (3.2% above the low).
Summary
CEO Ian Mortimer purchased $1.12 million of Xenon stock at $37.38 per share, his first open-market buy in at least 90 days, with the stock near its 52-week low.
Key Events · Ownership and Investor Activity · XENE
-
CEO Buys $1.12M in Open Market
Ian Mortimer, President and CEO, purchased 30,000 shares at $37.38 on September 30, 2026, for a total of $1,121,400.
-
First Insider Buy in 90 Days
This is the first open-market purchase by any insider in the last 90 days, during which insiders sold a net $1,066,379.
-
Purchase Near 52-Week Low
The buy was executed at $37.38, just above the 52-week low of $36.07, following a 30.7% single-day drop on September 18 after the MDD trial enrollment pause.
-
Post-Transaction Holdings
Mortimer now directly holds 49,923 shares, with an additional 14,300 shares held indirectly by his spouse.
Analysis · XENE · Life Sciences
President and CEO Ian Mortimer bought 30,000 shares at $37.38 on September 30, spending $1.12 million of his own money. The purchase comes just two weeks after Xenon shares plunged 30.7% on news that enrollment in the major depressive disorder trial was paused, and with the stock trading near its 52-week low. This is the first open-market buy by any insider in the last 90 days, against a backdrop of only insider selling during that period. The CEO's willingness to buy at these levels is a concrete statement of confidence in the company's lead asset, azetukalner, for which an NDA was recently filed in focal seizures.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.2% of the 1503 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XENE was trading at $37.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $36.07 to $72.66. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.